跳至主要内容
临床试验/CTRI/2022/07/043713
CTRI/2022/07/043713招募中3 期

Efficacy of high dosage of hepatitis B vaccination compared to standard dose in patient with inflammatory bowel disease: randomized controlled trial

Anupam Kumar Singh0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with a diagnosis of IBD (established by standard clinical, radiographic, endoscopic and histological criteria).
  • 2.Age >=18 years at the time of the first administration of the vaccine
  • 3.Seronegativity for hepatitis b surface antigen (HBsAg), antibodies to hepatitis B core protein (anti-HBc)
  • 4.No history of prior hepatitis b vaccination and titers for antibodies to hepatitis B surface antigen <10 mIU/L

排除标准

  • 1.History of HBV infection
  • 2.Previous vaccination against HBV (regardless of response)
  • 3.Any medical condition known to cause immunosuppression e.g. human immunodeficiency virus (HIV) infection, chronic kidney disease or malignancy
  • 4.Pregnant or lactating women
  • 5.Liver cirrhosis

研究者

发起方
Anupam Kumar Singh

相似试验